Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Oculus Innovative Sciences, Inc. (OCLS) Teams with Onset Therapeutics to Launch Revolutionary Dermatology Products

|Includes: Sonoma Pharmaceuticals, Inc. (SNOA)

Oculus, oculusis.com – the developers of powerful tissue care solutions based on the Microcyn® Technology platform, reported entry into a definitive agreement today with specialty pharmaceutical company Onset Therapeutics.

The agreement will see the two companies cooperating to strategically target the US dermatology market, utilizing OCLS’s Microcyn platform, in conjunction with Onset’s strong domestic commercial footprint to bring innovative products to an eager consumer space.

Initial opportunity in skin diseases like atopic dermatitis (a type of eczema) and related conditions, will quickly accelerate momentum under the engine of Onset’s sales team.

The global market for atopic dermatitis therapeutics in 2009 generated some $643M in revenues (GlobalData) and is expected to grow to $810M by 2016 at a 3.4% CAGR, largely due to a more diverse product mix, higher capacity and the increase in the number of new therapies.

The US atopic dermatitis therapeutics market in 2009 generated $402M in revenues and is expected to grow to $582M by 2016 at a 3.8% CAGR.

FDA clearance and subsequent US commercialization of two dermatology products by OCLS, a spray and a hydrogel based on the Microcyn Technology platform, stand as testimony of how viable this technology is for a variety of parallel markets like oral care and cosmeceuticals.

Solutions derived from the platform have demonstrated robust pathogen eliminating properties, including antibiotic-resistant strains of bacteria (MRSA/VRE), while increasing circulation and reducing inflammation/discomfort, augmenting the host’s natural healing process substantially.

Founder and CEO of OCLS, Hoji Alimi, hailed Onset as a respected and widely recognized “ideal” partner, projected a Q1 2011 date for the initial joint product launch and assured shareholders that subsequent revenue generation would occur in the same quarter.

General Manager of Onset, Doug Abel, expressed his excitement to be working with OCLS, explaining how much the partnership would enhance treatment options for patients and their physicians, creating a safe and powerful new set of healthier choices.

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net


Disclosure: no positions